Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: PrometheusTex who wrote (10028)	5/17/1999 8:14:00 AM
From: aknahow	Respond to of 17367

Caveat, I certainly do not know the correct answer. Just have reasons to doubt that mortality has been reduced when data stratified, in the absence of such data. BTW this item is of concern for all. Fraud in clinical testing. Perhaps Blugreen is right. The FDA should only test for safety. There is too much to keep track of when efficacy also needs to be proved. If trials were run for safety only the data load would go down and it would be easier to audit results. nytimes.com